Katsifis Gkikas, Bounas Andreas, Kandyli Anna, Koronaiou Maria, Antachopoulou Tina, Kyriakakis Antonios, Patrikos Dimos
Navl Hospital, Athens, Greece.
OLYMPION Hospital-General Clinic of Patras, Patras, Greece.
Mediterr J Rheumatol. 2024 Dec 31;35(4):579-607. doi: 10.31138/mjr.251024.lot. eCollection 2024 Dec.
The aim of the present analysis was to describe the clinical and demographic characteristics of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients from Greece who were enrolled in the global PROOF study, and their longitudinal follow-up over 5 years to determine the impact of the disease on quality of life and patient-reported outcomes.
PROOF was an observational study that enrolled recently diagnosed (<1 year) patients fulfilling the Assessment of SpondyloArthritis International Society classification criteria from rheumatology clinical practices from 29 countries across 6 different geographical regions.
Of the 100 Greek patients enrolled, 85 were classified based on local (investigator) evaluation of sacroiliac radiographs [AS: 56 (65.88%); nr-axSpA: 29 (34.12%)]. Higher prevalence of males in the AS (approximately 70%) and equal gender representation in the nr-axSpA patients were observed. There were variations in the clinical presentation, symptom duration, mean age at baseline, and HLA-B27 positivity between male and female patients. The majority of the patients were treated with TNF inhibitors from baseline to study end. Disease activity as well as patient-reported outcomes (functional index, quality of life, patient assessment of disease, and work productivity for employed patients) improved compared to baseline. Only 4 patients progressed to AS during the study.
This analysis provides longitudinal data from the patients enrolled in the global PROOF study from Greece for comparative purposes. The data from the Greek cohort can highlight challenges in the management of the SpA patients.
本分析旨在描述希腊强直性脊柱炎(AS)和非放射学轴向脊柱关节炎(nr-axSpA)患者的临床和人口统计学特征,这些患者参加了全球PROOF研究,并对其进行了5年的纵向随访,以确定疾病对生活质量和患者报告结局的影响。
PROOF是一项观察性研究,纳入了来自6个不同地理区域29个国家的风湿病临床实践中最近诊断(<1年)且符合国际脊柱关节炎学会分类标准的患者。
在纳入的100名希腊患者中,85名根据骶髂关节X线片的当地(研究者)评估进行分类[AS:56例(65.88%);nr-axSpA:29例(34.12%)]。观察到AS患者中男性患病率较高(约70%),而nr-axSpA患者中性别比例均衡。男性和女性患者在临床表现、症状持续时间、基线平均年龄和HLA-B27阳性率方面存在差异。从基线到研究结束,大多数患者接受了肿瘤坏死因子抑制剂治疗。与基线相比,疾病活动度以及患者报告结局(功能指数、生活质量、患者对疾病的评估以及在职患者的工作生产力)有所改善。在研究期间,只有4名患者进展为AS。
本分析提供了来自希腊参加全球PROOF研究患者的纵向数据,用于比较目的。希腊队列的数据可以突出脊柱关节炎患者管理中的挑战。